The situation you describe is why I tend to think
Post# of 148166
Licensing deals on HIV and the prostate test to fund CYDY's ambitions to go it alone as a cancer company (which may include GvHD).
Long-term SH looking to cash out should be happy, because the licensing deals will bring in non-dilutive cash and should support a higher SP. Those willing to hold longer-term also win, assuming cancer is what we think it can be.
Just my two cents.